Skip to main content
Windlas Biotech Limited logo

Windlas Biotech Limited — Investor Relations & Filings

Ticker · WINDLAS ISIN · INE0H5O01029 LEI · 3358008HGGLMCSC4GP83 BSE.NS Manufacturing
Open in API
Filings indexed 435 across all filing types
Latest filing 2025-02-28 Regulatory Filings
Country IN India
Listing BSE.NS WINDLAS

About Windlas Biotech Limited

https://www.windlasbiotech.com

Windlas Biotech Limited is a Contract Development and Manufacturing Organization (CDMO) providing integrated services from formulation development to commercial-scale production. The company specializes in manufacturing solid and liquid oral dosage forms, including tablets, capsules, sachets, and liquid orals. Its operations encompass three primary business verticals: CDMO services for domestic and multinational firms, trade generics, and over-the-counter (OTC) brands. Windlas maintains advanced research and development facilities focused on process optimization and complex generic formulations. The product portfolio covers diverse therapeutic areas such as gastrointestinal, cardiovascular, anti-diabetic, and respiratory health. The company emphasizes scalable manufacturing solutions and adherence to global quality standards to support the product lifecycles of its pharmaceutical partners.

Recent filings

Filing Released Lang Actions
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a short notice informing stock exchanges about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and provides details of the meeting date, type, and location. There is no financial data, no detailed report, no voting results, no management discussion, or other substantive content typical of financial reports. The document is an announcement of an event related to investor relations and regulatory compliance. Given the short length (2013 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS), which is a fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-28 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a formal letter addressed to stock exchanges (BSE and NSE) informing them about the schedule of analyst and institutional investor meetings. It references compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, specifically Regulation 30(6), which pertains to disclosure of material events or information. The content is an announcement of upcoming investor meetings and does not contain any financial data, report, or detailed presentation. The document length is short (2015 characters), and it serves as an informational notice rather than a report or transcript. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-28 English
Copy of Newspaper Publication
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is a letter from Windlas Biotech Limited addressed to the listing and compliance departments of BSE and NSE. It references the completion of dispatch of the Postal Ballot Notice dated February 11, 2025, and includes copies of newspaper advertisements published on February 20, 2025, regarding this dispatch. The content is an announcement about the dispatch of a postal ballot notice, which is related to shareholder voting procedures. There is no detailed financial data, management discussion, or report attached. The document is not a full report but an announcement of a procedural step in the shareholder voting process. Therefore, it fits best under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it relates to shareholder voting notices and their dispatch confirmation.
2025-02-20 English
Shareholders meeting
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Notice of Postal Ballot issued by Windlas Biotech Limited dated February 19, 2025. It is addressed to stock exchanges and shareholders, announcing the postal ballot process for re-appointment of Managing Director and Joint Managing Director. The document references compliance with SEBI Listing Regulations and Companies Act provisions, details the voting process, cut-off dates, and timelines for remote e-voting. It does not contain actual financial statements or results but is a formal notice seeking shareholder approval via postal ballot. This fits the definition of a Proxy Solicitation & Information Statement (PSI), as it is material sent to shareholders to provide information and request votes for a meeting/resolution. The document is lengthy (15,000 characters) and contains detailed procedural information, not just a brief announcement. Therefore, the correct classification is PSI with high confidence.
2025-02-19 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a detailed transcript of the Q3 FY25 earnings conference call for Windlas Biotech Limited, dated February 12, 2025. It includes management discussion of quarterly and nine-month financial results, operational updates, strategic outlook, and a Q&A session with analysts. The text explicitly mentions it is an "Earnings Conference Call Transcript" and contains detailed financial performance data and management commentary. This matches the definition of a Call Transcript (CT), which is a full text transcript of company conference calls such as earnings calls with Q&A. The document is about 15,000 characters long, contains substantive financial data and discussion, and is not merely an announcement or summary. Therefore, the correct classification is CT with high confidence.
2025-02-18 English
Analysts/Institutional Investor Meet/Con. Call Updates
Regulatory Filings Classification · 95% confidence The document is a letter from Windlas Biotech Limited addressed to stock exchanges, informing them about the recording of a conference call related to the company's un-audited financial results for the quarter and nine months ended December 31, 2024. It mentions that the audio recording has been uploaded on the company's website and that the transcript will be shared and uploaded later. The document does not contain the actual transcript or financial data but is an announcement about the availability of the conference call recording and forthcoming transcript. The document length is short (1776 characters), and it serves as an intimation under SEBI regulations. Therefore, it is best classified as a Regulatory Filing (RNS) since it is an announcement related to a conference call transcript but does not contain the transcript itself or substantive financial data.
2025-02-12 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.